根据转移性食道癌免疫化疗后的渐进模式进行精密疗法,最大限度地提高生存益处
Yingnan Liu1,2, Shuping Cheng2, Taotao Dong3
1Shandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250117, China.
iScience
|January 7, 2026
概括
转移性食道癌免疫治疗后耐药性的最佳治疗取决于进展模式. 放射治疗的好处是重复寡进化,而免疫治疗的重新挑战有助于重复多进化.
科学领域:
- 在瘤学瘤学.
- 医学治疗策略 医疗治疗策略
- 癌症的进展 癌症的进展
背景情况:
- 转移性食道癌往往会对一线免疫治疗产生抵抗力.
- 了解明显的进展模式对于优化后续治疗至关重要.
研究的目的:
- 根据免疫疗法抵抗后的进展模式,定义转移性食道癌的最佳治疗策略.
- 为了比较放射治疗与免疫治疗的疗效,在不同的进展子组中重新挑战.
主要方法:
- 患有对一线免疫疗法耐药的转移性食道癌患者被分为寡进和多进群.
- 小组包括重复的寡进 (REO),诱导的寡进 (INO),de-novo多进 (DNP) 和重复的多进 (REP).
- 在接受放射治疗 (RT) 和接受免疫治疗 (IO) 的患者之间比较了结局.
主要成果:
- 与对照组相比,接受RT的Oligoprogression患者的无进展生存期 (PFS) 和总生存期 (OS) 显着更长.
- REO子组特别受益于RT,改善了PFS和OS.
- 接受IO重复治疗的多发症患者表现出显著改善的PFS和OS,特别是在REP小组中.
结论:
- 放射治疗是转移性食道癌中重复寡进症 (REO) 患者的关键治疗方法.
- 免疫疗法重新挑战为重复多进化 (REP) 患者提供了显著的生存益处.
- 根据特定的进展模式量身定制治疗策略,免疫治疗后的耐药性对于改善患者的治疗结果至关重要.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.6K
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K